Sight Sciences Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Sight Sciences hat ein Gesamteigenkapital von $95.0M und eine Gesamtverschuldung von $34.2M, was einen Verschuldungsgrad von 36% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $143.6M bzw. $48.6M.

Wichtige Informationen

36.0%

Verhältnis von Schulden zu Eigenkapital

US$34.15m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$118.56m
Eigenkapital	US$94.96m
Gesamtverbindlichkeiten	US$48.64m
Gesamtvermögen	US$143.60m

Jüngste Berichte zur Finanzlage

Is Sight Sciences (NASDAQ:SGHT) A Risky Investment?

Jul 12

Recent updates

Sight Sciences, Inc. (NASDAQ:SGHT) Stocks Pounded By 26% But Not Lagging Industry On Growth Or Pricing

Nov 13

Why We're Not Concerned Yet About Sight Sciences, Inc.'s (NASDAQ:SGHT) 26% Share Price Plunge

Aug 15

Is Sight Sciences (NASDAQ:SGHT) A Risky Investment?

Jul 12

Sight Sciences, Inc. (NASDAQ:SGHT) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Dec 19

Some Analysts Just Cut Their Sight Sciences, Inc. (NASDAQ:SGHT) Estimates

Nov 19

Sight Sciences Grows Portfolio Amid Reimbursement Pressure

Aug 19

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: SGHTDie kurzfristigen Aktiva des Unternehmens ($140.5M) übersteigen seine kurzfristigen Passiva ($13.8M).

Langfristige Verbindlichkeiten: SGHTDie kurzfristigen Vermögenswerte des Unternehmens ($140.5M) übersteigen seine langfristigen Verbindlichkeiten ($34.8M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: SGHT über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: SGHT Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 120.6% auf 36% zurückgegangen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: SGHT auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt.

Vorhersage Cash Runway: SGHT verfügt über eine ausreichende Liquiditätsreserve für 2.8 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 9% pro Jahr abnimmt.

Sight Sciences Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is Sight Sciences (NASDAQ:SGHT) A Risky Investment?

Recent updates

Sight Sciences, Inc. (NASDAQ:SGHT) Stocks Pounded By 26% But Not Lagging Industry On Growth Or Pricing

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Sight Sciences, Inc. Announces Executive Appointments

Price target decreased by 14% to US$6.38

Chief Commercial Officer recently sold US$245k worth of stock

Chief Commercial Officer notifies of intention to sell stock

Sight Sciences, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Co-Founder recently sold US$76k worth of stock

CFO & Treasurer notifies of intention to sell stock

Price target increased by 14% to US$7.38

Why We're Not Concerned Yet About Sight Sciences, Inc.'s (NASDAQ:SGHT) 26% Share Price Plunge

Second quarter 2024 earnings: EPS exceeds analyst expectations

Sight Sciences, Inc. Narrows Earnings Guidance for the Full Year 2024

Sight Sciences, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Is Sight Sciences (NASDAQ:SGHT) A Risky Investment?

Co-Founder recently sold US$81k worth of stock

Sight Sciences, Inc. Announces Publication of New Analysis from the ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with Omni®? Across Mild, Moderate, and Advanced Glaucoma

CFO & Treasurer recently sold US$71k worth of stock

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Sight Sciences, Inc. Provides Revenue Guidance for the Second Half of 2024 and Re-Affirms Earnings Guidance for the Full Year 2024

Sight Sciences, Inc., Annual General Meeting, Jun 06, 2024

Sight Sciences, Inc. to Report Q1, 2024 Results on May 02, 2024

Sight Sciences, Inc. Announces the Publication of Large-Scale, Real-World Migs Study

Co-Founder recently sold US$64k worth of stock

Sight Sciences, Inc. Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT At the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS exceeds analyst expectations

Sight Sciences, Inc. Provides Earnings Guidance for the Year 2024

New minor risk - Insider selling

Sight Sciences, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Sight Sciences, Inc. Announces European Launch of the Ergo-Series of the OMNI Surgical System at the ESCRS Winter Meeting

Sight Sciences, Inc. announced that it expects to receive $65 million in funding

Co-Founder recently sold US$82k worth of stock

Co-Founder notifies of intention to sell stock

Sight Sciences, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Sight Sciences, Inc. (NASDAQ:SGHT) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Sight Sciences, Inc. Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease

Sight Sciences Announces the Acceptance for Publication of Gemini 2, A Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant Iop and Medication Reductions Enabled with the Omni® Surgical System Technology

Independent Chairman recently bought US$278k worth of stock

Some Analysts Just Cut Their Sight Sciences, Inc. (NASDAQ:SGHT) Estimates

Price target decreased by 49% to US$3.13

Sight Sciences, Inc. Withdraws Earnings Guidance for the Full Year 2023

Sight Sciences, Inc. Withdraws Earnings Guidance for the Full Year 2023

New minor risk - Market cap size

Sight Sciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Sight Sciences, Inc. Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma

Chief Operating Officer exercised options to buy US$130k worth of stock.

Sight Sciences, Inc. Revises Revenue Guidance for the Full Year 2023

Price target decreased by 8.1% to US$10.48

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Sight Sciences, Inc. Reaffirms Revenue Guidance for the Full Year 2023

Sight Sciences, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Price target decreased by 12% to US$12.80

Sight Sciences Announces Appointment of Catherine Mazzacco as New Director

Sight Sciences Two Year Multicenter Study Results Shows Sustained Reductions in Both Intraocular Pressure and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with A Procedure Enabled with the Omni Surgical System Technology

Sight Sciences, Inc. Announces 12-Month Results from the First Minimally Invasive Glaucoma Surgery

First quarter 2023 earnings: EPS exceeds analyst expectations

Sight Sciences Reaffirms Revenue Guidance for the Full Year 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Sight Sciences, Inc. Announces Executive Changes

Price target increased to US$14.60

Sight Sciences, Inc. Reports Improvements in Signs and Symptoms of Dry Eye Disease from A Single Tearcare

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Sight Sciences, Inc. Provides Revenue Guidance for Full Year 2022

Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI® Surgical System in Pseudophakic Glaucoma Patients

Sight Sciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Sight Sciences, Inc. Announces Publication of Data Showcasing Superior Symptoms Improvements with the TearCare(R) System Compared to Lipiflow in Patients with Advanced Dry Eye Disease (DED)

Sight Sciences Announces Completion of Enrollment in SAHARA, a Randomized Clinical Trial of the TearCare(R) System vs Restasis

Sight Sciences Introduces the Sion(Tm) Surgical Instrument -- the First Bladeless Device Used in Goniotomy

Sight Sciences Grows Portfolio Amid Reimbursement Pressure

Sight Sciences, Inc. Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI(R) Surgical System in Patients with Open Angle Glaucoma